BCRX FY 2012 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+33.9% YoY

Gross Profit

$26M99.5% margin

Operating Income

-$34M-128.9% margin

Net Income

-$39M-148.6% margin

EPS (Diluted)

$-0.79

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$38M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$57M

Total Liabilities

$58M

Stockholders' Equity

-$393M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$20M	+33.9%
Gross Profit	$26M	$20M	+33.2%
Operating Income	-$34M	-$50M	+31.7%
Net Income	-$39M	-$57M	+31.4%